[Psoriasis: advances and challenges in 2015].

Abstract excerpt

Over the course of the last decade advances in the understanding the pathogenesis of psoriasis have resulted in the development of many novel, safe and effective biologics. However, a significant proportion of patients respond inadequately to biologics--defined by failing to respond initially (lack of efficacy) or secondary failure--with diminishing response over time (loss of efficacy). Over the past years...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biological Products
• Share to Drug Design
• Share to Phenotype